Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study

View through CrossRef
Background/Objectives: Biologic therapies have transformed the management of inflammatory bowel disease (IBD), but their high cost has prompted the introduction of biosimilars. Although switching from biologic originators to biosimilars is increasingly common, real-world evidence remains limited. We aimed to explore the safety and efficacy of switching between biologic originators and biosimilars. Methods: We conducted a retrospective chart review of patients with IBD between 2015 and 2025. Adult patients receiving adalimumab-adaz or adalimumab-atto were included. Patients who were non-medically switched once from adalimumab originator (Humira®) to any biosimilar were classified as group A. Patients who also switched back to originator (multiple switches) were classified as group B. The outcomes of the study were safety and efficacy of the biosimilars. Logistic regression identified switching predictors. Results: A total of 237 patients were included in the study. The number of patients in group A and group B was 208 and 58 patients, respectively. Sustained clinical remission was achieved in 198 (95.4%) of group A and 54 (93.6%) of group B participants. Sustained normalization of inflammatory markers was also comparable, occurring in 190 (91.5%) of group A and 54 (92.3%) of group B participants. No treatment-emergent AEs, infections, or treatment discontinuations were reported in either group (0%). Regression analysis identified older age and prior immunomodulator use as significant predictors of switching. Conclusions: Multiple switches of adalimumab biosimilars can be safely undertaken without increasing the risk of adverse reactions or treatment failure. This study provides meaningful evidence to guide policy and physician confidence in biosimilar interchangeability as a sustainable IBD therapeutic strategy.
Title: Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study
Description:
Background/Objectives: Biologic therapies have transformed the management of inflammatory bowel disease (IBD), but their high cost has prompted the introduction of biosimilars.
Although switching from biologic originators to biosimilars is increasingly common, real-world evidence remains limited.
We aimed to explore the safety and efficacy of switching between biologic originators and biosimilars.
Methods: We conducted a retrospective chart review of patients with IBD between 2015 and 2025.
Adult patients receiving adalimumab-adaz or adalimumab-atto were included.
Patients who were non-medically switched once from adalimumab originator (Humira®) to any biosimilar were classified as group A.
Patients who also switched back to originator (multiple switches) were classified as group B.
The outcomes of the study were safety and efficacy of the biosimilars.
Logistic regression identified switching predictors.
Results: A total of 237 patients were included in the study.
The number of patients in group A and group B was 208 and 58 patients, respectively.
Sustained clinical remission was achieved in 198 (95.
4%) of group A and 54 (93.
6%) of group B participants.
Sustained normalization of inflammatory markers was also comparable, occurring in 190 (91.
5%) of group A and 54 (92.
3%) of group B participants.
No treatment-emergent AEs, infections, or treatment discontinuations were reported in either group (0%).
Regression analysis identified older age and prior immunomodulator use as significant predictors of switching.
Conclusions: Multiple switches of adalimumab biosimilars can be safely undertaken without increasing the risk of adverse reactions or treatment failure.
This study provides meaningful evidence to guide policy and physician confidence in biosimilar interchangeability as a sustainable IBD therapeutic strategy.

Related Results

P85 Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis
P85 Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis
Abstract Biological drugs have revolutionized the treatment of immune-mediated inflammatory diseases. Clinical experience and evidence suggest that biosimilars can b...
Abstract PS19-03: Contemporary patterns of Medicare Utilization and Spending on Herceptin and its Biosimilars in Breast Cancer
Abstract PS19-03: Contemporary patterns of Medicare Utilization and Spending on Herceptin and its Biosimilars in Breast Cancer
Abstract Introduction: A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved refe...
Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars
Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars
Introduction: The first biosimilar entered the Canadian market in 2009 and the first ophthalmic biosimilar was approved in 2022. In 2022, the Alliance for Safe Biologic Medicines (...
Perspectives toward biosimilars among oncologists: A Malaysian survey
Perspectives toward biosimilars among oncologists: A Malaysian survey
Introduction Biosimilars confer significant cost-saving advantages and expand patients’ access to biologic therapies in cancer care. In line with the increasing...
US prescribers’ attitudes and perceptions about biosimilars
US prescribers’ attitudes and perceptions about biosimilars
Introduction: In the United States (US), a legal framework for approving biosimilars was established via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). At t...

Back to Top